BGLC vs. OPGN, PMD, DMTK, XGN, BTCY, MBRX, AEZS, BCDA, GHSI, and PHXM
Should you be buying BioNexus Gene Lab stock or one of its competitors? The main competitors of BioNexus Gene Lab include OpGen (OPGN), Psychemedics (PMD), DermTech (DMTK), Exagen (XGN), Biotricity (BTCY), Moleculin Biotech (MBRX), Aeterna Zentaris (AEZS), BioCardia (BCDA), Guardion Health Sciences (GHSI), and PHAXIAM Therapeutics (PHXM). These companies are all part of the "medical" sector.
OpGen (NASDAQ:OPGN) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, community ranking, profitability, media sentiment, valuation and analyst recommendations.
In the previous week, OpGen had 1 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 4 mentions for OpGen and 3 mentions for BioNexus Gene Lab. BioNexus Gene Lab's average media sentiment score of 0.93 beat OpGen's score of 0.92 indicating that OpGen is being referred to more favorably in the media.
OpGen received 301 more outperform votes than BioNexus Gene Lab when rated by MarketBeat users.
BioNexus Gene Lab has a net margin of -26.90% compared to BioNexus Gene Lab's net margin of -852.18%. OpGen's return on equity of -32.99% beat BioNexus Gene Lab's return on equity.
BioNexus Gene Lab has higher revenue and earnings than OpGen. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than OpGen, indicating that it is currently the more affordable of the two stocks.
2.7% of OpGen shares are held by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are held by institutional investors. 1.3% of OpGen shares are held by company insiders. Comparatively, 6.8% of BioNexus Gene Lab shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
BioNexus Gene Lab beats OpGen on 8 of the 13 factors compared between the two stocks.
Get BioNexus Gene Lab News Delivered to You Automatically
Sign up to receive the latest news and ratings for BGLC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BGLC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioNexus Gene Lab Competitors List
Related Companies and Tools
